“Global Antacids Market is anticipated to grow on account of growing geriatric population suffering from GERD, unhealthy eating habits, and easy accessibility of the medicine as an OTC drug”, says new Visiongain report

04 September 2019
Pharma

Visiongain has launched a new pharma report Antacids Market Report 2019-2029: By Dosage Form (Tablets, Liquid, Others), by Distribution Channel (Retail, Online, Hospital) and by Region

Global Antacids Market is anticipated to grow on account of growing geriatric population suffering from GERD, unhealthy eating habits, and easy accessibility of the medicine as an OTC drug. The global Antacids market is anticipated to grow at a lucrative CAGR of 4.1% and anticipated to reach USD 9.24 Billion by 2029.

Antacids are a category of drugs which has been in the market for several years. Initially, they were first-line protection against peptic ulcer disease; however, the discovery of proton pump inhibitors revolutionized peptic ulcer disease therapy. Antacid use is currently limited to relieve heartburn associated with mild intermittent GERD (gastroesophageal reflux disease). The estimated incidence of heartburn in North America at least once a week varies from 18% to 28%, with 25% of adolescents reporting daily heartburn.

Increasing prevalence of GERD is anticipated to affect the global market over the forecast period. Also, as per reports of the Gut journal in the year 2017, the prevalence of GERD was approximately 9% to 26% in Europe, 18% to 28% in North America, 9% to 33% in Middle East, 3% to 8% in East Asia, 23% in South America and 12% in Australia. Furthermore, growing awareness about GERD is anticipated to fuel the growth of global antacids market.

North America retains most market share followed by Europe and will continue to dominate in the future as a consequence of growing incidence of digestive disorders combined with consumer knowledge of antacid products. According to the CDC, in 2017, there were around 32.3 million visits to emergency departments with digestive system illnesses as the main diagnosis. Furthermore, the presence of developed economies within the region is fueling the growth of North America antacids market.

Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the presence of large patient pool suffering from digestive problems, availability of effective treatment methods, consumer awareness about the availability of these products and rising disposable income. Also, the presence of key players is anticipated to contribute to market growth over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., First Aid Only, GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble, Reckitt Benckiser Group plc, Sanofi-Aventis LLC, Sun Pharmaceuticals Ltd. And Takeda Pharmaceutical Company Limited among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

 

Recent News

“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.

20 September 2019

Read

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
Do NOT follow this link or you will be banned from the site!